[REVISION HISTORY]
Medical research on brain injury blood biomarkers
1 recorded revision of this situation.
What changed
2026-11-14 08:23 UTC → 2026-11-19 20:08 UTC ·
added
removed
Medical researchers in the United States are developing blood-based methods to identify various forms of brain injury. Initial research from the University of Pittsburgh focused on using two specific proteins, Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1), to detect traumatic brain injuries (TBI). This method aims to identify injuries when standard CT scans appear normal, potentially improving triage in emergency departments. Subsequent findings from Washington University in St. Louis identified a protein fragment, eMTBR-tau243, which may assist in diagnosing chronic traumatic encephalopathy (CTE) in living patients. While preliminary, studies suggest that levels of this biomarker rise alongside the severity of CTE, though it may also be elevated in cases of Alzheimer’s disease. Recent research published in JAMA indicates that this protein marker may correlate with advanced-stage CTE, a finding some researchers described as a potential “game changer.” While the test shows promise for identifying advanced pathology, it has not yet proven reliable for early-stage detection. A systematic review and meta-analysis published in JAMA Network Open further noted that CTE pathology is rare in individuals without a history of contact sports, appearing in only 0.66% of community brain bank donors. However, researchers suggest that if these rates are extrapolated, more than 1 million Americans could be living with the disease, underscoring the necessity for effective diagnostic tools.
Versions
- 2026-11-19 20:08 UTC Medical research on brain injury blood biomarkers
- 2026-11-14 08:23 UTC Medical research on brain injury blood biomarkers
Select a version to see what changed compared to the one before it.